These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2009-016645-25||Diagnosis of coronary artery disease with Rubidium-82 PET and Technetium-99m MIBI SPET : a head to head comparison, versus coronary CT angiography||2013-11-21||due-trials|
|Ongoing||2011-005049-11||A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, ...||not-yet-due|
|Not reported||2014-002741-21||Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).||2016-08-01||due-trials|
|Ongoing||2017-003432-37||Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor||not-yet-due|
|Exempt||2017-004034-29||A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with p...||not-yet-due|
|Exempt||2018-004727-37||A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with ad...||not-yet-due|